Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 15/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199870 | 0.89 | PDE3B (0.48) | PDE3BPDE3AENPP1 | |
| SCHEMBL12775783 | 0.87 | PDE3B (0.57) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL13199882 | 0.77 | PDE3B (0.37) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL13199873 | 0.77 | ENPP1 (0.40) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL12775903 | 0.76 | PDE3B (0.36) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL20220690 | 0.75 | TTBK1 (0.49) | — | |
| SCHEMBL10813255 | 0.74 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL2015028 | 0.74 | PDE3B (0.53) | PDE3BPDE3AENPP1ADORA1ENPP3 | |
| SCHEMBL23326745 | 0.72 | ENPP1 (0.44) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL12775877 | 0.71 | ENPP1 (0.39) | ENPP1ENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PDE3B 1744/4885PDE3A 1801/4885ENPP1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.